Compare Nuwellis Inc (NUWE) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Taskus Inc — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Taskus Inc is far larger — about 328.8× Nuwellis Inc's market cap, and Taskus Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Taskus Inc for 34 Days on average.
| NUWE | TASK | |
|---|---|---|
Market Cap | $2.20M | $723.41M |
Volume | 121,544 | 201,303 |
Sector | Health | Technology |
52-Week High | $146.65 | $14.69 |
52-Week Low | $0.68 | $4.57 |
Typical Hold Time | 26 Days | 34 Days |
Enterprise Value | -$1.52M | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
TaskUs trades at $7.89, down 0.88% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin of 8.75%. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected. Analyst consensus is bullish with 55% buy ratings and $9.33 price target, representing 18% upside potential.
The stock presents value opportunity with solid profitability and AI services growth offsetting Trust & Safety declines. Key risks include labor cost pressures and client concentration. Positive cash flow generation and institutional accumulation support the bullish case, though technical weakness suggests near-term consolidation may continue before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
